Sitagliptin (Januvia™) is a new oral agent approved by the US FDA ... the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic ...

Objectives The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies ... There were no patients prescribed oral GLP-1 analogues. For this study, we only included patients from ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1, or glucagon-like peptide-1, is a hormone produced in the digestive system that regulates appetite and insulin secretion. Medications like Ozempic and Wegovy, categorized as GLP-1 agonists ...

Next to artificial intelligence, one of the biggest investment themes over the past few years has been a class of anti-obesity drugs called glucagon-like peptide 1 (GLP-1) therapies, better known ...